CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Qurient Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Qurient Co Ltd
801, C Dong, 242, Pangyo-ro, Bundang-gu
Phone: +82 3180601600p:+82 3180601600 Seongnam, 13487  South Korea Ticker: 115180115180
Business Summary
Qurient Co Ltd is a Korea-based company primarily engaged in the research and sales of pharmaceuticals. The Company operates its business through two segments. The Pharmaceutical Research and Development Business segment primarily engages in the development of new drugs such as anticancer drugs, antibiotics, and anti-inflammatory drugs. The Pharmaceutical Distribution Business segment primarily engages in the distribution of prescription drugs.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Gi YeonNam 44 1/1/2015 1/1/2015
Vice President, Director Jung SikHwang 44 1/1/2015 1/1/2015
Internal Auditor Yun SuKang 46
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 22 (As of 12/31/2019)
Outstanding Shares: 32,287,282 (As of 8/23/2024)
Shareholders: 16,316
Stock Exchange: KDQ
Fax Number: +82 3180601649


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024